Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography

NeuroImage

Volumn 45, Issue 3, 2009, Pages 687-693

  Ma, Kuo Hsing ^a   Huang, Wen Sheng ^b   Kuo, Yu Yeh ^a   Peng, Chi Jiun ^b   Liou, Nien Hsien ^a   Liu, Ren Shyan ^c   Hwang, Jeng Jong ^c   Liu, Jiang Chuan ^a   Chen, Haw Jan ^d   Shiue, Chyng Yann ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

4 18F ADAM; 5,7 Dihydroxytryptamine; Autoradiography; p Chloroamphetamine; Paroxetine; Positron emission tomography; Serotonin transporters

Indexed keywords

5,7 DIHYDROXYTRYPTAMINE; CHLORAMPHETAMINE; CONTRAST MEDIUM; N,N DIMETHYL 2 (2 AMINO 4 FLUOROPHENYLTHIO)BENZYLAMINE F 18; PAROXETINE; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; BENZYLAMINE DERIVATIVE; N,N DIMETHYL 2 (2 AMINO 4 FLUOROPHENYLTHIO)BENZYLAMINE; N,N-DIMETHYL-2-(2-AMINO-4-FLUOROPHENYLTHIO)BENZYLAMINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; FRONTAL CORTEX; HYPOTHALAMUS; MALE; MESENCEPHALON; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; ANIMAL; BRAIN; METABOLISM; SCINTISCANNING; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; BENZYLAMINES; BRAIN; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TISSUE DISTRIBUTION;

EID: 61649093533     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2008.12.060     Document Type: Article

References (41)

1. Björklund A., Baumgarten H.G., and Rensch A. 5,7-Dihydroxytryptamine: improvement of its selectivity for serotonin neurons in the CNS by pretreatment with desipramine. J. Neurochem. 24 (1975) 833-835
2. 18F]fluoromethyl)-(+)-McN5652. Neuropsychopharmacology 28 (2003) 2010-2019
3. Caille S., Stinus L., Espejo E.F., De Deurwaerdere P., Spampinato U., and Koob G.F. Inhibition of 5-HT neurotransmission increases clonidine protective effects on naloxone-induced conditioned place aversion in morphine-dependent rats. Neuropsychopharmacology 28 (2003) 276-283
4. 123I-ADAM SPECT study. Psychopharmacology 189 (2006) 145-153
5. Coppen A. The biochemistry of affective disorders. Br. J. Psychiatry. 113 (1967) 1237-1264
6. Cryan J.F., O'Leary O.F., and Jin S.H. Norepinephrine-deficient mice lack responses to antidepressant drugs including selective serotonin reuptake inhibitors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8187-8191
7. Dourish C.T., Vickers S.P., Clifton P.G., and Tecott L.H. Effect of targeted deletion of the 5-HT2C receptor gene on meal patterns and on hypophagia induced by d-fenfluramine. Soc. Neurosci. 23 (1997) 514
8. Ferris R.M., Brieaddy L., Mehta N., Hollingsworth E., Rigdon G., Wang C., Soroko F., Wastila W., and Cooper B. Pharmacological properties of 403U76, a new chemical class of 5-hydroxytryptamine- and noradrenaline-reuptake inhibitor. J. Pharm. Pharmacol. 47 (1995) 775-781
9. Fuller R.W. Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem. Res. 17 (1992) 449-456
10. 11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 47 (2003) 123-133
11. Glatz K., Mössner R., Heils A., and Lesch K.P. Glucocorticoid-regulated human serotonin transporter (5-HTT) expression is modulated by the 5-HTT gene-promotor-linked polymorphic region. J. Neurochem. 86 (2003) 1072-1078
12. Hartvig P., Bergström M., Antoni G., and Langström B. Positron emission tomography and brain monoamine neurotransmission - entries for study of drug interactions. Curr. Pharm. Des. 8 (2002) 1417-14134
13. 11C]DASB. Eur. J. Nucl. Med. 27 (2000) 1719-1722
14. 11C]AFA). Nucl. Med. Biol. 31 (2004) 727-738
15. Huang Y., Bae S.A., Zhu Z., Guo N., Roth B.L., and Laruelle M. Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. J. Med. Chem. 48 (2005) 2559-2570
16. 18F-ADAM PET in healthy and drug-naïve depressant subjects. J. Nucl. Med. 48 (2007) 261P
17. Jarkas N., McConathy J., Votaw J.R., Voll R.J., Malveaux E., Camp V.M., Williams L., Goodman R.R., Kilts C.D., and Goodman M.M. Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography. Nucl. Med. Biol. 32 (2005) 75-86
18. Jonsson G. Chemical neurotoxins as denervation tools in neurobiology. Annu. Rev. Neurosci. 3 (1980) 169-187
19. 11C McN 5652. Psychopharmacology 164 (2002) 341-348
20. Kutscher C.L., and Yamamoto B.K. A frequency analysis of behavior components of the serotonin syndrome produced by p-chloroamphetamine. Pharmacol. Biochem. Behav. 11 (1979) 611-616
21. 11C]DASB binding after tranylcypromine-induced increase in serotonin concentration: positron emission tomography studies in monkeys and rats. Synapse 61 (2007) 440-449
22. Mann J.J., Huang Y.-Y., Underwood M.D., Kassir S.A., Oppenheim S., Kelly T.M., Dwozk A.J., and Arango V. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch. Gen. Psychiatry 57 (2000) 729-738
23. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., Kupfer D.J., and Reynold C.F. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 18 (1998) 407-430
24. Mössner R., Daniel S., Albert D., Heils A., Okladnova O., Schmitt A., and Lesch K.P. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem. Int. 36 (2000) 197-202
25. Mössner R., Daniel S., Schmitt A., Albert D., and Lesch K.P. Modulation of serotonin transporter function by interleukin-4. Life Sci. 68 (2001) 873-880
26. 18F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamin e). J. Med. Chem. 45 (2002) 4716-4723
27. th ed. (1998), Academic Press, Burlington, MA
28. 18F]-ADAM) for imaging serotonin transporters. Appl. Radiat. Isot. 66 (2008) 625-631
29. Scanlon S.M., Williams D.C., and Schloss P. Membrane cholesterol modulates serotonin transporter activity. Biochemistry (Mosc) 40 (2001) 10507-10513
30. Scheffel U., Dannals R.F., Suehiro M., Ricaurte G.A., Carroll F.I., Kuhar M.J., and Wagner Jr. H.N. Development of PET/SPECT ligands for the serotonin transporter. NIDA Res. Monogr. 138 (1994) 111-130
31. 18F]fluorophenylthio)benzylamine as a serotonin transporter imaging agent. Appl. Radiat. Isot. 58 (2003) 183-191
32. 18F-ADAM): an improved PET radioligand for serotonin transporters. J. Nucl. Med. 44 (2003) 1890-1897
33. 18F-ADAM in monkeys. J. Nucl. Med. 48 (2007) 298P
34. Snyder S.H., and Ferris C.D. Novel neurotransmitters and their neuropsychiatric relevance. Am. J. Psychiatry 157 (2000) 1738-1751
35. 11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci. 53 (1993) 883-892
36. 11C](+)McN5652. Synapse 20 (1995) 37-43
37. Vorhees C.V., Schaefer G.J., and Barrett R.J. P-chloroamphetamine: behavioral effects of reduced cerebral serotonin in rats. Pharmacol. Biochem. Behav. 3 (1975) 279-284
38. 18F]fluoropr opoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters. Nucl. Med. Biol. 35 (2008) 447-458
39. 11C-labeled 2-(phenylthio)araalkylamines. J. Med. Chem. 43 (2000) 3103-3110
40. 123I-ADAM in mice treated with fluoxetine and serotonin reuptake inhibitors. Nucl. Med. Biol. 31 (2004) 557-562
41. Zhou F.C., Tao-Cheng J.H., Segu L., Patel T., and Wang Y. Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res. 805 (1998) 241-254